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Introduction
The genes CDKN2A and CDKN2B (encoding the tumor 
suppressors p15, p16 and p19) are commonly deleted 
or hypermethylated in T-cell acute lymphoblastic leu-
kemia (ALL) [1, 2]. It is common to have a co-deletion 
of methylthioadenosine phosphorylase (MTAP) as the 
MTAP gene is located adjacent to the CDKN2A/B locus 
[3]. Studies have shown that around 70 % of T-cell ALL 
cases have MTAP deletions [4, 5]. MTAP cleaves the 
natural by-product of polyamine synthesis, 5′-deoxy-5′-
methylthioadenosine, to adenine and 5-methylthioribose-
1-phosphate, which are converted to adenine nucleo-
tides and methionine [5] (Fig. 1). Cells lacking MTAP 
are unable to salvage adenine through this pathway and 
are reliant on the de novo synthesis pathway for their 
purine requirements. MTAP has also been implicated as 
a possible tumor suppressor [6]. This variation between 
MTAP+/+ cells and tumor MTAP−/− cells led to several 
studies showing that MTAP−/− cells are more sensitive to 
inhibitors of de novo purine synthesis [7].
Currently, the antifolate methotrexate is commonly used 
as a component of treatment options in pediatric and T-cell 
ALL in adults [8]. In contrast to the 80 % survival rate in 
children with T-cell ALL [9], curability of adults with this 
disease is poor [10]. Patients usually respond to intensive 
chemotherapy, but there is a high relapse rate. Allogenic 
transplantation may be effective, but many patients relapse 
or are burdened with graft-versus-host disease. Therefore, 
there is a need for newer and more effective treatments, both 
for adults and children who relapse from first-line treatment. 
There has been much research on the effect of MTAP expres-
sion on different leukemia and lymphoma types, and there 
is still much more information to uncover regarding the best 
drugs and optimal dosages to use when treating patients [11].
Abstract 
Purpose To investigate the effectiveness of a combination 
of 6-thioguanine (6-TG) and pralatrexate (PDX) in methyl-
thioadenosine phosphorylase (MTAP)-deficient T-cell acute 
lymphoblastic leukemia (T-cell ALL).
Methods CCRF-CEM (MTAP−/−) and Molt4 (MTAP+/+) 
T-cell ALL cell lines were treated with 6-TG or PDX and 
evaluated for efficacy 72 h later. NOD/SCID gamma mice 
bearing CEM or Molt4 xenografts were treated with 6-TG 
and PDX alone or in combination to evaluate antitumor 
effects.
Results CEM cells were more sensitive to 6-TG and PDX 
in vitro than Molt4. In vivo, CEM cells were very sensi-
tive to PDX and 6-TG, whereas Molt4 cells were highly 
resistant to 6-TG. A well-tolerated combination of PDX 
and 6-TG achieved significant tumor regression in CEM 
xenografts.
Conclusions The loss of MTAP expression may be thera-
peutically exploited in T-cell ALL. The combination of 
6-TG and PDX, with the inclusion of leucovorin rescue, 
allows for a safe and effective regimen in MTAP-deficient 
T-cell ALL.
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Pralatrexate (PDX) is a second generation antifolate that 
targets dihydrofolate reductase and inhibits de novo purine 
synthesis through depletion of 10-formyl tetrahydrofolate 
[12, 13]. PDX has a high affinity for reduced folate car-
rier-1 and is better retained by cells via conversion to poly-
glutamylates [14]. 6-thioguanine (6-TG), an antimetabolite 
analog of guanine, also targets de novo purine synthesis [5, 
15].
In this study, we tested single-agent PDX and 6-TG 
as well as in combination to treat MTAP+/+ (Molt4) and 
MTAP−/− (CEM) T-cell ALL cell lines and xenografts. 
CEM xenografts were found to be more sensitive to PDX 
treatment than Molt4 xenografts. CEM xenografts were 
also more sensitive to 6-TG, while Molt4 xenografts were 
resistant to 6-TG. Results of the combination of PDX, 
6-TG and leucovorin against CEM xenografts show prom-
ise as an effective therapy for MTAP-deficient T-cell ALL.
Materials and methods
Immunoblot
Log-phase CEM and Molt4 cells were harvested by cen-
trifugation after culture in RPMI 1640 supplemented with 
10 % FBS. After brief centrifugation, cell pellets were lysed 
in RIPA buffer containing a commercial protease inhibitor 
mix (Roche, Nutley, NJ, USA). After protein quantifica-
tion by the Bradford protein assay (Bio-Rad Laborato-
ries, Hercules, CA, USA), proteins were resolved by 10 % 
SDS-PAGE and transferred onto a nitrocellulose membrane 
(Bio-Rad Laboratories). After blocking the membrane 
with 5 % nonfat dry milk prepared in Tris-buffered saline 
+0.1 % Tween-20, the membrane was incubated with the 
desired primary antibody according to the manufacturer’s 
































Fig. 1  Loss of MTAP sensitizes cells to 6-thioguanine and de novo 
purine synthesis inhibitors. a MTAP allows for the salvage of ade-
nine and methionine from methylthioadenosine (MTA) produced 
during polyamine synthesis. Purine analog drugs such as 6-thiogua-
nine (6-TG) must compete with adenine for PRPP in the formation 
of their nucleotide derivatives, mediated by APRT for adenine and 
HGPRT for 6-TG. b In cells lacking MTAP, salvage of both methio-
nine and adenine is prevented. These cells should become more 
sensitive to 6-TG as more PRPP allows greater synthesis of active 
6-TG nucleotides well as de novo purine synthesis inhibitors such 
as pralatrexate, which inhibit the production of AMP. 6-TG 6-thio-
guanine, AMP adenosine monophosphate, APRT adenosine phos-
phoribosyltransferase, ATP adenosine triphosphate, HGPRT hypox-
anthine-guanine phosphoribosyltransferase, PDX pralatrexate, PPi 
pyrophosphate, PRPP phosphoribosyl pyrophosphate, MTA methyl-
thioadenosine, MTAP methylthioadenosine phosphorylase. Modified 
from Reference [4]
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Tris-buffered saline +0.1 % Tween-20 and incubated for 
2 h at room temperature with the appropriate peroxidase-
conjugated secondary antibody. Bands were visualized 
using an enhanced chemiluminescence kit (Pierce, Thermo 
Fisher Scientific, Rockford, IL, USA). Anti-MTAP (42-
T), anti-α-tubulin (B-7) and anti-mouse secondary were 
purchased from Santa Cruz Biotechnologies (Dallas, TX, 
USA).
In vitro cytotoxicity
Five-thousand Molt4 or CCRF-CEM (CEM) cells per 
well were plated in 96-well plates in RPMI 1640 media 
(Gibco) supplemented with 10 % dialyzed FBS (Invitro-
gen). Media containing drug was added, and plates were 
incubated for 72 h. The CellTiter 96 Aqueous One Solution 
(Promega) assay was used to assess cell viability at the end 
of the experiment according to the manufacturers’ proto-
col. Experiments were performed in triplicate. Data were 
analyzed using the GraphPad Prism 6 software package 
(GraphPad Software Inc.).
In vivo experiments
Eight-to-ten-week-old male NOD/SCID gamma mice 
(a gift from Dr. Sharon Pine) were injected subcutane-
ously into the right flank with 15 million CEM or Molt4 
cells in a 1:1 mixture of Matrigel (BD Biosciences) and 
PBS (Gibco). Mice were monitored until palpable tumors 
reached a size of 400 mm3. Mice were then randomized 
and split into treatment cohorts of eight mice as described. 
Drugs for study were prepared in the following manner: 
6-thioguanine was dissolved in 0.15 M NaCl and heated 
at 70 °C. NaOH was added until a clear solution formed; 
the solution was sterile filtered with a 0.22-µm filter. 
Leucovorin was sourced from the Rutgers Cancer Institute 
of New Jersey’s pharmacy, and pralatrexate was provided 
by Spectrum Pharmaceuticals.
General toxicity was monitored through weight loss. 
Tumor dimensions were measured every 2–4 days using 
calipers, and tumor volume was calculated using the fol-
lowing equation: Volume = (width2) × (length/2). All 
animal experiments were approved by the Rutgers Institu-
tional Animal Care and Use Committee.
Results
We used two T-cell ALL cell lines to determine the effect 
MTAP expression has on drug sensitivity. Molt4 cells 
express MTAP, whereas CEM cells do not express MTAP 
(Fig. 2a). Both cell lines were treated with 6-TG or PDX 
for 72 h and assayed for viability. As expected, CEM cells 
were more sensitive to both 6-TG and PDX, although only 
6-TG showed a sizable (~fivefold) separation between the 
IC50 for each cell line (Fig. 2b, c). This enhanced sensi-
tivity can be attributed to the increase in 6-TG nucleo-
tide incorporation in MTAP−/− cells through the action of 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT) 
[16] (Fig. 1b).
Single‑agent in vitro treatment
To evaluate the response of these drugs in vivo, NOD/SCID 
gamma mice bearing advanced CEM or Molt4 xenografts 
were treated with PDX and 6-TG. Large xenografts used 
in a previous experiment showed dramatic responses to 
PDX treatment. In response to a dosing schedule of 10 mg/
kg 6-TG on days 1–5 (Fig. 3a, solid line), CEM xenografts 
exhibited a rapid loss in tumor burden. Molt4 xenografts 
Fig. 2  Cells lacking MTAP 
are more sensitive to 6-TG and 
pralatrexate. a Western blots 
showing the MTAP status of 
CEM (MTAP−/−) and Molt4 
(MTAP+/+) cells. Dose response 
curves show percent of viable 
CEM or Molt4 cells remaining 
after 72 h of treatment with b 
6-TG or c PDX. All experiments 
were performed in triplicate
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demonstrated little response to 6-TG treatment (Fig. 3a, 
dashed line). Compared to the large response CEM xeno-
grafts had to 6-TG treatment, the lack of even moderate 
regression in Molt4 xenografts was notable. Treatment with 
60 mg/kg PDX on days 1 and 5 resulted in tumor regres-
sion for both cell lines (Fig. 3b). Both treatments were tol-
erated with moderate weight loss (data not shown).
Treatment of mice bearing xenografts of CEM cells
Having established that MTAP+/+ xenografts have lim-
ited sensitivity to 6-TG, we focused our efforts on treat-
ing MTAP−/− xenografts with a combination of 6-TG and 
PDX. The enhanced incorporation of 6-TG into nucleo-
tides and lack of adenine salvage in addition to the reli-
ance of de novo synthesis of purines in MTAP−/− cells 
predicts potent sensitivity of these cells to 6-TG and PDX 
in combination. To test this, large CEM xenografts were 
treated using a schedule of 60 mg/kg PDX on days 1 and 
5 and/or 10 mg/kg 6-TG on days 1–8. There was a com-
plete regression of all CEM xenografts in the combination 
cohort (Fig. 4a). However, this combination schedule was 
very toxic, resulting in an unacceptable decline in body-
weight, necessitating killing of these animals (Fig. 4b). 
The increase in 6-TG dosing also lead to a rapid decline 
in bodyweight several days after the last treatment in the 
6-TG cohort, indicating that a cumulative toxic dose was 
reached (Fig. 4b).
Despite this toxicity, the complete response observed 
in the combination cohort was encouraging. We previ-
ously established that PDX toxicity can be abrogated using 
leucovorin (LV) rescue without compromising antitumor 
effects [17]. Therefore, we included LV into the 6-TG and 
PDX combination to lessen general toxicity but preserve 
antitumor activity. In this experiment, to demonstrate that 
decreasing the intensity of the regimen and treating the 
mice with only one cycle could result in tumor regres-
sion without toxicity, we treated cohorts consisting of 
60 mg/kg PDX on day 1 + 50 mg/kg leucovorin on days 
2 and 3; 10 mg/kg 6-TG on days 1–3; 60 mg/kg PDX on 
day 1 + 50 mg/kg leucovorin on days 2 and 3 + 10 mg/
kg 6-TG on days 1–3 to better monitor the effects of the 
combination. Significant antitumor activity was seen in the 
combination cohort, with almost complete tumor regres-
sion and a prolonged recovery period (Fig. 5a), despite 
the administration of only one cycle. All treatment cohorts 
were well tolerated, and no significant loss of bodyweight 
occurred (Fig. 5b).
Fig. 3  CEM xenografts are 
more sensitive to PDX and 
6-TG than Molt4 xenografts. 
Mice bearing large CEM or 
MOLT4 xenografts were admin-
istered a 10 mg/kg 6-TG on 
days 1–5 or b 60 mg/kg PDX 
on days 1 and 5. Tumor volume 
was measured every few days
Fig. 4  The combination of 6-TG and PDX was not tolerable, despite 
significant efficacy. Mice bearing advanced CEM xenografts were 
treated with 10 mg/kg 6-TG on days 1–8 and/or 60 mg/kg PDX on 
days 1 and 5. Mice treated with 6-TG alone or in combination exhib-
ited severe weight loss and had to be killed. Xenografts on control 
mice reached an unacceptable size, and mice were euthanized accord-
ing to the institutional protocols. Tumor volume (a) and bodyweight 
(b) were measured
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Discussion
Although pralatexate is approved for treatment of T-cell 
lymphomas, studies of this drug to treat T-cell ALL have 
not as yet been reported. A recent study from the Children’s 
Oncology Group showed that high-dose MTX with LV res-
cue enhanced the outcome of patients with T-cell ALL [18]. 
Given that a high percentage of pediatric patients with T-cell 
ALL lack MTAP, this may be the explanation for the clinical 
benefit observed with MTX. Our previous study showed that 
PDX was even more effective than MTX in the treatment of 
CEM T-cell lymphoma that lacked MTAP. We also showed 
that subsets of peripheral T-cell lymphoma lack MTAP in a 
high percent of cases [4]. The study presented here provides a 
strong rationale for using the combination of pralatrexate and 
6-thioguanine for the treatment of leukemias and lymphomas 
lacking MTAP [5]. Based on these data, a clinical study using 
this combination strategy has been initiated in T-cell ALL.
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